Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA, Maity TK, Cultraro CM, Misra V, Zhang X, Ade C, Gao S, Milewski D, Nguyen KD, Ebrahimabadi MH, Hanada KI, Khan J, Sahinalp C, Yang JC, Guha U. Qi YA, et al. Among authors: cultraro cm. Mol Cell Proteomics. 2021;20:100136. doi: 10.1016/j.mcpro.2021.100136. Epub 2021 Aug 13. Mol Cell Proteomics. 2021. PMID: 34391887 Free PMC article.
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U. Maity TK, et al. Among authors: cultraro cm. Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3. Cancer Discov. 2015. PMID: 25735773 Free PMC article.
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, Guha U. Venugopalan A, et al. Among authors: cultraro cm. Oncotarget. 2016 Aug 23;7(34):54137-54156. doi: 10.18632/oncotarget.11021. Oncotarget. 2016. PMID: 27494838 Free PMC article.
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U. Biswas R, et al. Among authors: cultraro cm. Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001263. doi: 10.1101/mcs.a001263. Cold Spring Harb Mol Case Stud. 2016. PMID: 27900369 Free PMC article.
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U. Zhang X, et al. Among authors: cultraro cm. Mol Cell Proteomics. 2017 May;16(5):891-910. doi: 10.1074/mcp.M117.067439. Epub 2017 Mar 22. Mol Cell Proteomics. 2017. PMID: 28331001 Free PMC article.
Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Zhang X, Nguyen KD, Rudnick PA, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro CM, Fenyö D, Guha U. Zhang X, et al. Among authors: cultraro cm. Mol Cell Proteomics. 2019 Apr;18(4):622-641. doi: 10.1074/mcp.RA118.001266. Epub 2019 Jan 7. Mol Cell Proteomics. 2019. PMID: 30617155 Free PMC article.
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown AL, Goncearenco A, Panchenko AR, Biswas R, Thomas A, Rajan A, Carter CA, Kleiner DE, Hewitt SM, Khan J, Prokunina-Olsson L, Guha U. Roper N, et al. Among authors: cultraro cm. Cell Rep. 2019 Mar 5;26(10):2651-2666.e6. doi: 10.1016/j.celrep.2019.02.028. Cell Rep. 2019. PMID: 30840888 Free PMC article.
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Roper N, Brown AL, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, El Meskini R, Ohler ZW, Maity TK, Venugopalan A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Panchenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Roper N, et al. Among authors: cultraro cm. Cell Rep Med. 2020 Apr 21;1(1):100007. doi: 10.1016/j.xcrm.2020.100007. Cell Rep Med. 2020. PMID: 32483558 Free PMC article. Clinical Trial.
Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, Pitts S, Keswani M, Gao S, Nguyen KDP, Cowart J, Kirkali F, Wu C, Guha U. Zhang X, et al. Among authors: cultraro cm. Cancer Res. 2021 Jun 1;81(11):3051-3066. doi: 10.1158/0008-5472.CAN-20-2435. Epub 2021 Mar 16. Cancer Res. 2021. PMID: 33727228 Free PMC article.
35 results